Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Feld

Showing results (371-380 of 451) with videos related to

Pageof 46
Sort By:
Open Forum Infectious Diseases|February 17, 2018
Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 StudiesJason Grebely, Jordan J Feld, David Wyles, et al.
Hepatology (Baltimore, Md.)|January 18, 2013
Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infectionJason Grebely, Jordan J Feld, Tanya Applegate, et al.
Journal of Viral Hepatitis|November 27, 2025
Pharmacist-Led Hepatitis C Diagnosis and Rapid Management-In Community (PHARM-C): Results From a Phase IV Nonblinded Randomised Controlled TrialMia J Biondi, Camelia I Capraru, Ben Harper, et al.
Journal of Viral Hepatitis|May 21, 2019
Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6Eric Lawitz, Edward Gane, Jordan J Feld, et al.
Journal of Gastroenterology and Hepatology|March 19, 2016
Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosisRaoel Maan, Remziye Zaim, Adriaan J van der Meer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2020
Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion UpdateJessica P Hwang, Jordan J Feld, Sarah P Hammond, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 9, 2020
Reducing Read Time of Point-of-Care Test Does Not Affect Detection of Hepatitis C Virus and Reduces Need for Reflex RNADavid Smookler, Aaron Vanderhoff, Mia J Biondi, et al.
Hepatology Communications|December 6, 2023
IL-2 produced by HBV-specific T cells as a biomarker of viral control and predictor of response to PD-1 therapy across clinical phases of chronic hepatitis BConan Chua, Loghman Salimzadeh, Ann T Ma, et al.
Gastroenterology|October 27, 2015
Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 InfectionMark S Sulkowski, Hugo E Vargas, Adrian M Di Bisceglie, et al.
Hepatology (Baltimore, Md.)|September 16, 2020
Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral TherapyAnna S Lok, Robert Perrillo, Christina M Lalama, et al.
Pageof 46

Showing results (371-380 of 451) with videos related to

Sort By:
Pageof 46
Open Forum Infectious Diseases|February 17, 2018
Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 StudiesJason Grebely, Jordan J Feld, David Wyles, et al.
Hepatology (Baltimore, Md.)|January 18, 2013
Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infectionJason Grebely, Jordan J Feld, Tanya Applegate, et al.
Journal of Viral Hepatitis|November 27, 2025
Pharmacist-Led Hepatitis C Diagnosis and Rapid Management-In Community (PHARM-C): Results From a Phase IV Nonblinded Randomised Controlled TrialMia J Biondi, Camelia I Capraru, Ben Harper, et al.
Journal of Viral Hepatitis|May 21, 2019
Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6Eric Lawitz, Edward Gane, Jordan J Feld, et al.
Journal of Gastroenterology and Hepatology|March 19, 2016
Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosisRaoel Maan, Remziye Zaim, Adriaan J van der Meer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2020
Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion UpdateJessica P Hwang, Jordan J Feld, Sarah P Hammond, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 9, 2020
Reducing Read Time of Point-of-Care Test Does Not Affect Detection of Hepatitis C Virus and Reduces Need for Reflex RNADavid Smookler, Aaron Vanderhoff, Mia J Biondi, et al.
Hepatology Communications|December 6, 2023
IL-2 produced by HBV-specific T cells as a biomarker of viral control and predictor of response to PD-1 therapy across clinical phases of chronic hepatitis BConan Chua, Loghman Salimzadeh, Ann T Ma, et al.
Gastroenterology|October 27, 2015
Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 InfectionMark S Sulkowski, Hugo E Vargas, Adrian M Di Bisceglie, et al.
Hepatology (Baltimore, Md.)|September 16, 2020
Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral TherapyAnna S Lok, Robert Perrillo, Christina M Lalama, et al.
Pageof 46